Skip to main content
Erschienen in: Calcified Tissue International 4/2003

01.10.2003 | Laboratory Investigation

Hypertrophy of Vascularized Bone Isograft in Rats Treated with Cyclosporine A

verfasst von: T. Tsubone, M. Shigetomi, K. Ihara, K. Ikeda, L. Merida, T. Ohno, T. Sugiyama, S. Kawai

Erschienen in: Calcified Tissue International | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the effects of cyclosporine A (CsA) on vascularized tibio-fibula isograft between 12-week-old male Lewis rats. After transplantation, 45 rats were randomly allocated to one of the following 7 treatment groups: (1) 4-week vehicle (n = 5), (2) 4-week CsA (n = 5), (3) 8-week vehicle (n = 10), (4) 8-week CsA (n = 10), (5) 4-week CsA followed by 4-week vehicle (n = 5), (6) 16-week vehicle (n = 5), or (7) 4-week CsA followed by 12-week vehicle (n = 5). In soft X-ray and micro-computed tomography examination, hypertrophic change of the grafted bones was apparent in the 4- and 8-week CsA groups. Mineral apposition rate and bone formation rate of the grafted bones in the 4-week CsA group were markedly higher than those in the 4-week vehicle group. In the 4- and 8-week CsA groups, however, bone mineral density (BMD) of the grafted bones was lower and strength of the reconstructed bones was weaker than the 4- and 8-week vehicle groups. Urinary deoxypyridinoline (DPD) level was higher in the 4- and 8-week CsA groups than in the 4- and 8-week vehicle groups. The group of 4-week CsA followed by 4-week vehicle had a level of urinary DPD equal to the 8-week vehicle group, but their BMD of the grafted bones was lower and strength of the reconstructed bones was weaker than the 8-week vehicle group. By contrast, the group of 4-week CsA followed by 12-week vehicle had BMD of the grafted bones and strength of the reconstructed bones similar to the 16-week vehicle group. These findings demonstrate that short-term CsA treatment induces hypertrophic change of vascularized bone graft with high-turnover bone loss, and strength of the reconstructed bone is gradually restored after the cessation of CsA treatment.
Literatur
1.
Zurück zum Zitat Epstein, S 1996Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton.J Bone Miner Res1117PubMed Epstein, S 1996Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton.J Bone Miner Res1117PubMed
2.
Zurück zum Zitat Rodino, MA, Shane, E 1998Osteoporosis after organ transplantation.Am J Med104459469PubMed Rodino, MA, Shane, E 1998Osteoporosis after organ transplantation.Am J Med104459469PubMed
3.
Zurück zum Zitat Ramsey-Goldman, R, Dunn, JE, Dunlop, DD, Stuart, FP, Abecassis, MM, Kaufman, DB, Langman, CB, Salinger, MH, Sprague, SM 1999Increased risk of fracture in patients receiving solid organ transplants.J Bone Miner Res14456463PubMed Ramsey-Goldman, R, Dunn, JE, Dunlop, DD, Stuart, FP, Abecassis, MM, Kaufman, DB, Langman, CB, Salinger, MH, Sprague, SM 1999Increased risk of fracture in patients receiving solid organ transplants.J Bone Miner Res14456463PubMed
4.
Zurück zum Zitat Leidig-Bruckner, G, Hosch, S, Dodidou, P, et al. 2001Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.Lancet357342347PubMed Leidig-Bruckner, G, Hosch, S, Dodidou, P,  et al. 2001Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.Lancet357342347PubMed
5.
Zurück zum Zitat Delmas, PD 2001Osteoporosis in patients with organ transplants: a neglected problem.Lancet357325326CrossRefPubMed Delmas, PD 2001Osteoporosis in patients with organ transplants: a neglected problem.Lancet357325326CrossRefPubMed
6.
Zurück zum Zitat Movsowitz, C, Epstein, S, Fallon, M, Ismail, F, Thomas, S 1988Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration.Endocrinology12325712577PubMed Movsowitz, C, Epstein, S, Fallon, M, Ismail, F, Thomas, S 1988Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration.Endocrinology12325712577PubMed
7.
Zurück zum Zitat Buchinsky, FJ, Ma, Y, Mann, GN, Rucinski, B, Bryer, HP, Romero, DF, Jee, WS, Epstein, S 1996T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia.Endocrinology13722782285PubMed Buchinsky, FJ, Ma, Y, Mann, GN, Rucinski, B, Bryer, HP, Romero, DF, Jee, WS, Epstein, S 1996T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia.Endocrinology13722782285PubMed
8.
Zurück zum Zitat Goodman, GR, Dissanayake, IR, Bowman, AR, Pun, S, Ma, Y, Jee, WS, Bryer, HP, Epstein, S 2001Transforming growth factor-ß administration modifies cyclosporine A-induced bone loss.Bone28583588PubMed Goodman, GR, Dissanayake, IR, Bowman, AR, Pun, S, Ma, Y, Jee, WS, Bryer, HP, Epstein, S 2001Transforming growth factor-ß administration modifies cyclosporine A-induced bone loss.Bone28583588PubMed
9.
Zurück zum Zitat Epstein, S, Dissanayake, IR, Goodman, GR, Bowman, AR, Zhou, H, Ma, Y, Jee, WS 2001Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat.Calcif Tissue Int68240247PubMed Epstein, S, Dissanayake, IR, Goodman, GR, Bowman, AR, Zhou, H, Ma, Y, Jee, WS 2001Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat.Calcif Tissue Int68240247PubMed
10.
Zurück zum Zitat Orcel, P, Bielakoff, J, Modrowski, D, Miravet, L, de Vernejoul, MC 1989Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone.J Bone Miner Res4387391PubMed Orcel, P, Bielakoff, J, Modrowski, D, Miravet, L, de Vernejoul, MC 1989Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone.J Bone Miner Res4387391PubMed
11.
Zurück zum Zitat del Pozo, E, Graeber, M, Elford, P, Payne, T 1990Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A.Arthritis Rheum33247252PubMed del Pozo, E, Graeber, M, Elford, P, Payne, T 1990Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A.Arthritis Rheum33247252PubMed
12.
Zurück zum Zitat Han, CS, Wood, MB, Bishop, AT, Cooney III, WP 1992Vascularized bone transfer.J Bone Joint Surg Am7414411449PubMed Han, CS, Wood, MB, Bishop, AT, Cooney III, WP 1992Vascularized bone transfer.J Bone Joint Surg Am7414411449PubMed
13.
Zurück zum Zitat Wei, FC, El-Gammal, TA, Lin, CH, Ueng, WN 1997Free fibula osteoseptocutaneous graft for reconstruction of segmental femoral shaft defects.J Trauma43784792PubMed Wei, FC, El-Gammal, TA, Lin, CH, Ueng, WN 1997Free fibula osteoseptocutaneous graft for reconstruction of segmental femoral shaft defects.J Trauma43784792PubMed
14.
Zurück zum Zitat Duffy, GP, Wood, MB, Rock, MG, Sim, FH 2000Vascularized free fibular transfer combined with autografting for the management of fracture nonunions associated with radiation therapy.J Bone Joint Surg Am82544554PubMed Duffy, GP, Wood, MB, Rock, MG, Sim, FH 2000Vascularized free fibular transfer combined with autografting for the management of fracture nonunions associated with radiation therapy.J Bone Joint Surg Am82544554PubMed
15.
Zurück zum Zitat Shin, AY, Bishop, AT 2001Vascular anatomy of the distal radius: implications for vascularized bone grafts.Clin Orthop3836073PubMed Shin, AY, Bishop, AT 2001Vascular anatomy of the distal radius: implications for vascularized bone grafts.Clin Orthop3836073PubMed
16.
Zurück zum Zitat Doi, K, Akino, T, Shigetomi, M, Muramatsu, K, Kawai, S 1994Vascularized bone allografts: review of current concepts.Microsurgery15831841PubMed Doi, K, Akino, T, Shigetomi, M, Muramatsu, K, Kawai, S 1994Vascularized bone allografts: review of current concepts.Microsurgery15831841PubMed
17.
Zurück zum Zitat Doi, K, Kawai, S, Shigetomi, M 1996Congenital tibial pseudoarthrosis treated with vascularised bone allograft.Lancet347970971 Doi, K, Kawai, S, Shigetomi, M 1996Congenital tibial pseudoarthrosis treated with vascularised bone allograft.Lancet347970971
18.
Zurück zum Zitat Hofmann, GO, Kirschner, MH, Wagner, FD, Brauns, L, Gonschorek, O, Bühren, V 1998Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints: first clinical experiences.Transplant Proc3027542761CrossRefPubMed Hofmann, GO, Kirschner, MH, Wagner, FD, Brauns, L, Gonschorek, O, Bühren, V 1998Allogeneic vascularized transplantation of human femoral diaphyses and total knee joints: first clinical experiences.Transplant Proc3027542761CrossRefPubMed
19.
Zurück zum Zitat Hofmann, GO, Kirschner, MH 2000Clinical experience in allogeneic vascularized bone and joint allografting.Microsurgery20375383CrossRefPubMed Hofmann, GO, Kirschner, MH 2000Clinical experience in allogeneic vascularized bone and joint allografting.Microsurgery20375383CrossRefPubMed
20.
Zurück zum Zitat Merida, L, Shigetomi, M, Ihara, K, Tsubone, T, Ikeda, K, Yamaguchi, A, Sugiyama, T, Kawai, S 2002Effects of Vitamin D analog, 22-oxa-1, 25-Dihydroxyvitamin D3, on bone reconstruction by vascularized bone allograft.Bone30422427CrossRefPubMed Merida, L, Shigetomi, M, Ihara, K, Tsubone, T, Ikeda, K, Yamaguchi, A, Sugiyama, T, Kawai, S 2002Effects of Vitamin D analog, 22-oxa-1, 25-Dihydroxyvitamin D3, on bone reconstruction by vascularized bone allograft.Bone30422427CrossRefPubMed
21.
Zurück zum Zitat Ohno, T, Shigetomi, M, Ihara, K, Ikeda, K, Tsubone, T, Matsunaga, T, Sugiyama, T, Kawai, S 2003Effects of cerivastatin on vascularized allogenic bone transplantation in rats treated with cyclosporine A.Calcif Tissue Int725056CrossRefPubMed Ohno, T, Shigetomi, M, Ihara, K, Ikeda, K, Tsubone, T, Matsunaga, T, Sugiyama, T, Kawai, S 2003Effects of cerivastatin on vascularized allogenic bone transplantation in rats treated with cyclosporine A.Calcif Tissue Int725056CrossRefPubMed
22.
Zurück zum Zitat Shigetomi, M, Doi, K, Kuwata, N, Muramatsu, K, Yamamoto, H, Kawai, S 1994Experimental study on vascularized bone allografts for reconstruction of massive bone defects.Microsurgery15663670PubMed Shigetomi, M, Doi, K, Kuwata, N, Muramatsu, K, Yamamoto, H, Kawai, S 1994Experimental study on vascularized bone allografts for reconstruction of massive bone defects.Microsurgery15663670PubMed
23.
Zurück zum Zitat de Boer, HH, Wood, MB 1989Bone changes in the vascularised fibular graft.J Bone Joint Surg Br71374378PubMed de Boer, HH, Wood, MB 1989Bone changes in the vascularised fibular graft.J Bone Joint Surg Br71374378PubMed
24.
Zurück zum Zitat Tamai, S 1995Experimental vascularized bone transplantations.Microsurgery16179185PubMed Tamai, S 1995Experimental vascularized bone transplantations.Microsurgery16179185PubMed
Metadaten
Titel
Hypertrophy of Vascularized Bone Isograft in Rats Treated with Cyclosporine A
verfasst von
T. Tsubone
M. Shigetomi
K. Ihara
K. Ikeda
L. Merida
T. Ohno
T. Sugiyama
S. Kawai
Publikationsdatum
01.10.2003
Erschienen in
Calcified Tissue International / Ausgabe 4/2003
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-002-2147-6

Weitere Artikel der Ausgabe 4/2003

Calcified Tissue International 4/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.